Introduction Neuroimaging biomarkers are important for early diagnosis of Alzheimer's
disease, and comparing multimodality neuroimaging to autopsy data is essential. Methods …

Alzheimer's disease biomarkers are widely accepted as surrogate markers of underlying
neuropathological changes. However, few studies have evaluated whether preclinical …

Imaging-pathological correlation studies show that in vivo amyloid-β (Aβ) positron emission
tomography (PET) strongly predicts the presence of significant Aβ pathology at autopsy. We …

INTRODUCTION To examine the extent to which positron emission tomography (PET)‐,
cerebrospinal fluid (CSF)‐, and plasma‐related amyloid‐β/tau/neurodegeneration (A/T/N) …

Introduction This article reviews the work done in the Alzheimer's Disease Neuroimaging
Initiative positron emission tomography (ADNI PET) core over the past 5 years, largely …

Background: PET imaging using [18F] fluorodeoxyglucose (FDG) and [11C] Pittsburgh
compound B (PIB) have been proposed as biomarkers of Alzheimer disease (AD), as have …

Objective To examine the feasibility of using cross-sectional PET to identify cognitive
decliners among β-amyloid (Aβ)-negative cognitively normal (CN) elderly adults. Methods …

Objective: To examine neurodegenerative imaging biomarkers in Alzheimer disease (AD)
dementia from middle to old age. Methods: Persons with AD dementia and elevated brain β …

Imaging biomarkers can be used to screen participants for Alzheimer's disease clinical trials.
To test the predictive values in clinical progression of neuropathology change (amyloid …

Objective The purpose of this study was to compare the diagnostic accuracy of antemortem
11C‐Pittsburgh compound B (PIB) and 18F‐fluorodeoxyglucose (FDG) positron emission …